Logo
x

Search

Subscribe Now

All Posts by Date

PharmaShots' Key Highlights of Third Quarter 2022

PharmaShots' Key Highlights of Third Quarter 2022

  • September 29, 2022
Sanofi and Regeneron’s Dupixent (dupilumab) Receive the US FDA’s Approval as 1L Treatment for Prurigo Nodularis

Sanofi and Regeneron’s Dupixent (dupilumab) Receive the US FDA’s Approval as 1L Treatment for Prurigo Nodularis

  • September 29, 2022
Ventus Entered into an Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program to Treat Cardiometabolic Diseases

Ventus Entered into an Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program to Treat Cardiome...

  • September 29, 2022
Ascletis Reports First Patient Dosing in the P-IIb Expansion Cohort of ASC22 (envafolimab) for Chronic Hepatitis B

Ascletis Reports First Patient Dosing in the P-IIb Expansion Cohort of ASC22 (envafolimab) for Chronic Hepatitis B

  • September 29, 2022
MaxCyte Signed a Non-Exclusive License Agreement with Vertex to Advance CTX001 Transfusion-Dependent Beta Thalassemia or Sickle Cell Disease

MaxCyte Signed a Non-Exclusive License Agreement with Vertex to Advance CTX001 Transfusion-Dependent Beta Thalassemia or Sickle Ce...

  • September 29, 2022
Disease of the Month: Duchenne Muscular Dystrophy (DMD)

Disease of the Month: Duchenne Muscular Dystrophy (DMD)

  • September 29, 2022
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.